ArticleCancers2021

Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma.

Benjamin Emil Stubbe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.